Finasteride

Introduction Overview

Generic Name

finasteride

Brand Name

Proscar

Dosage Form

oral tablet

Drug Class

5-alpha-reductase inhibitors

Pharmacokinetics

Absorption:
Finasteride demonstrates rapid and extensive absorption when administered orally. Peak plasma concentrations are typically reached within 1 to 2 hours post-dose. Its oral bioavailability is approximately 65%, unaffected significantly by food intake, making it convenient for administration without regard to meals. The drug's absorption profile ensures consistent plasma levels with once-daily dosing.

Distribution:
Finasteride exhibits moderate plasma protein binding, primarily to albumin, in the range of 90%. It readily penetrates various tissues, with a notable affinity for androgen-sensitive tissues such as the prostate, seminal vesicles, liver, and skin. The volume of distribution is relatively modest, reflecting its tissue selectivity and limited accumulation outside target organs. Distribution to the central nervous system is minimal, which correlates with its localized pharmacodynamic effects.

Metabolism:
Finasteride undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme CYP3A4 isoform. The metabolism involves oxidation and reduction pathways producing both active and inactive metabolites. These metabolic transformations are critical for drug clearance and reduce systemic exposure to the parent compound. Hepatic function impairment may alter its metabolic clearance, necessitating caution or dosage adjustment in patients with liver disease.

Elimination:
The drug and its metabolites are excreted predominantly through feces (~57%) and urine (~39%). The elimination half-life averages around 5 to 6 hours in healthy adult males, supporting its once-daily dosing regimen. Steady-state concentrations are achieved within 2 weeks of continuous therapy. Renal impairment does not significantly affect finasteride elimination; however, data in severe hepatic impairment are limited. The drug’s elimination profile minimizes the accumulation risk, even with prolonged therapy.

Dosage Forms

Available Dosage Forms:
Proscar is available exclusively as an oral tablet formulated for once-daily dosing. The tablets are scored and contain 5 mg of finasteride. This single-dose strength is designed specifically for the treatment of benign prostatic hyperplasia.

Dosages for Adults and Adolescents:
The standard and approved dosage for adults suffering from benign prostatic hyperplasia is 5 mg taken orally once daily. Dose adjustments are generally unnecessary due to the drug's pharmacokinetic consistency and safety profile. Proscar is indicated only for use in adult males; it is not indicated for pediatric populations or females.

Specific Patient Populations:
Proscar is contraindicated in women and children due to the risk of hormonal effects and teratogenicity, particularly concerning male fetal development during pregnancy. Patients with hepatic dysfunction should use the medication cautiously, monitoring for altered drug metabolism. No specific dose modifications are mandated for elderly patients or those with renal impairment.

Additional Formulation Information:
No alternative formulations, such as oral liquids, extended-release tablets, or injectable forms of Proscar, are commercially available. The tablet form is the sole delivery method, providing reliable plasma levels with high patient compliance.

Mechanism Of Action

Proscar (finasteride) functions as a potent and specific inhibitor of type II 5-alpha-reductase, an intracellular enzyme responsible for the conversion of testosterone to dihydrotestosterone (DHT) in androgen-sensitive tissues. DHT is a more potent androgen compared to testosterone and critically involved in the pathophysiology of benign prostatic hyperplasia (BPH). By inhibiting this irreversible oxidation-reduction reaction, finasteride effectively reduces intraprostatic and serum DHT levels.

The suppression of DHT results in decreased androgenic stimulation of prostatic cells, leading to gradual shrinkage of the enlarged prostate tissue. This reduction in prostate volume alleviates bladder outlet obstruction, improves urinary flow, and diminishes BPH symptoms over time. The mechanism is selective without significant suppression of circulating testosterone, which preserves overall androgenic balance.

On a cellular level, finasteride reduces the DHT-mediated activation of androgen receptors in prostate stromal and epithelial cells, decreasing proliferation signals and promoting apoptosis of hyperplastic tissue. This biochemical interruption of androgen receptor signaling pathways is central to its therapeutic effects.

Comparative studies demonstrate that finasteride’s mechanism is distinct yet complementary to alpha-adrenergic blockers, which work by relaxing smooth muscle tone. Combination therapy employing finasteride and alpha-blockers provides enhanced symptom control by targeting both static and dynamic components of BPH. Clinical trials corroborate significant decreases in prostate volume and improved urinary symptoms with finasteride, highlighting its role in modifying the disease's natural course.

Pharmacological Actions

Selective inhibition of type II 5-alpha-reductase enzyme, reducing dihydrotestosterone (DHT) synthesis.
Decreases prostate gland size through inhibition of androgen-mediated cellular proliferation.
Lowers serum and intraprostatic DHT concentrations, attenuating benign prostatic hyperplasia progression.
Modulates androgen receptor signaling pathways leading to reduced cellular hyperplasia and increased apoptosis.
Improves urinary flow rates and alleviates lower urinary tract symptoms in men with enlarged prostate.
Reduces the risk of acute urinary retention and the need for BPH-related surgery.
Demonstrates tissue specificity by targeting androgen-sensitive prostate tissues with minimal systemic hormonal disruption.
Used adjunctively with alpha-blockers to provide dual mechanism action (static and dynamic components) in BPH.
Has a prolonged duration of action with once-daily oral dosing supported by pharmacokinetic properties.
Minimal interaction with other hormone pathways, preserving testosterone levels and minimizing systemic side effects.

Therapeutic Or Clinical Uses

Treatment of benign prostatic hyperplasia (BPH) to improve urinary symptoms in men with enlarged prostate.
Reduction of prostate volume in men with symptomatic BPH to relieve bladder outlet obstruction.
Prevention of acute urinary retention in men suffering from moderate to severe BPH.
Decreasing the need for BPH-related surgical interventions by mitigating disease progression.
Used as monotherapy or as part of combination therapy with alpha-adrenergic blockers (e.g., doxazosin) for enhanced symptom control.
Management of lower urinary tract symptoms attributed to BPH including hesitancy, weak stream, and nocturia.
Off-label, finasteride is used for male pattern baldness (under different brand names), but Proscar specifically is for BPH.
Reduction of prostatitis symptoms in certain clinical contexts where DHT modulation is beneficial.
Part of long-term management strategy for chronic BPH patients unsuitable or unwilling to undergo surgical therapies.
May be used to reduce the risk of sudden urinary retention complications in high-risk patient populations.

Side Or Adverse Effects

Decreased libido (reduced sexual interest) is a commonly reported side effect.
Erectile dysfunction, including difficulty achieving or maintaining an erection.
Reduced ejaculatory volume or abnormal ejaculation patterns.
Breast tenderness and breast enlargement (gynecomastia) in male patients.
Possible depression or mood changes reported in some users.
Rare reports of male breast cancer, necessitating vigilance for breast lumps or nipple discharge.
Allergic reactions including urticaria, rash, or swelling of face and extremities are infrequent but serious.
Potential decrease in semen quality and fertility that may impact conception during treatment.
Sexual adverse effects may persist even after discontinuation of therapy in rare cases.
Mild gastrointestinal disturbances such as nausea or abdominal discomfort occasionally reported.
Headaches and dizziness have been reported but are generally transient.
Fatigue and asthenia may occur in some patients but are not common.
Hypersensitivity reactions, though rare, can include itching and swelling.
Rarely, palpitation and changes in heartbeat have been documented.
Injection site reactions are not applicable as Proscar is oral only.

Precautions

Women who are pregnant or may become pregnant must avoid any exposure to Proscar due to risk of teratogenic effects on a male fetus.
Tablets should not be handled by pregnant women, especially if crushed or broken, to prevent dermal absorption.
Patients with a history of liver disease should inform their healthcare provider due to potential altered metabolism.
Finasteride is contraindicated in pediatric and female populations; use only in adult men.
Baseline prostate specific antigen (PSA) levels must be established before initiating treatment and monitored regularly.
Patients should be educated that Proscar does not provide immediate symptom relief; effects develop over months.
Any new breast masses, pain, or nipple discharge during therapy should prompt immediate medical evaluation.
Inform the physician of any history of prostate cancer as finasteride may alter PSA test results and cancer risk profile.
Close monitoring is required for patients at risk of or diagnosed with prostate abnormalities.
Patients should not share their medication and adhere strictly to prescribed dosing schedules.
Avoid discontinuing Proscar abruptly without consulting a healthcare professional as it may affect disease control.
Caution in patients with allergy to finasteride or similar agents such as dutasteride.
Concomitant use with other medications should be communicated to the physician to avoid interactions.
Patients with depression or mood disorders should be monitored during therapy for symptom exacerbation.
Regular follow-up visits are essential for dose evaluation and side effect monitoring.

Warnings

Finasteride can be absorbed through the skin and cause serious birth defects if a pregnant woman is exposed.
Do not handle broken or crushed tablets if you are or may become pregnant; wash skin immediately if contact occurs.
Use may increase the risk of development of high-grade prostate cancer; informed consent and regular screening is required.
Monitor patients for signs and symptoms of male breast cancer such as lumps, pain, or nipple discharge.
Not indicated for use in women or children; exposure is contraindicated in these populations.
Patients should be aware that Proscar affects PSA screening accuracy and should inform healthcare providers when undergoing testing.
Emergency medical attention is necessary if any allergic reactions occur, including swelling and difficulty breathing.
Discontinue use and seek physician consultation if symptoms suggest prostate cancer progression or new breast changes.
Some sexual side effects may persist after stopping therapy; patients should discuss risks and benefits with their doctor.
Dose doubling or self-adjustment is contraindicated and may increase adverse effect risk.
Storage conditions require original container preservation away from moisture, heat, and light for drug stability.
Regular prostate examinations and laboratory monitoring are critical during therapy.
Avoid sharing medication with others, even if symptoms appear similar.
Patient education must emphasize the chronic nature of BPH and that Proscar is part of long-term management.
The drug has not been studied or recommended for pediatric use; strict adult male use only.

Contraindication

Known hypersensitivity to finasteride or any component of the tablet formulation.
Women, particularly those who are or may become pregnant, due to risk of teratogenicity and fetal harm.
Use in children or adolescents is contraindicated given the lack of safety and efficacy data.
Patients with a prior history of prostate cancer with high-grade tumors must avoid use without oncologic consultation.
Any previous allergic reactions to 5-alpha-reductase inhibitors such as dutasteride.
Severe hepatic impairment may contraindicate use or require careful consideration.
Active breast cancer or history of male breast abnormalities precludes safe use.
Patients undergoing PSA testing for prostate cancer diagnosis who cannot be monitored closely.
Use is contraindicated in patients who are unwilling to undergo regular clinical and laboratory follow-ups.
Patients with unexplained genital bleeding or urinary obstruction requiring surgery may need alternative therapies.
Known hypersensitivity reactions including anaphylaxis with previous finasteride exposure.
Concomitant use with medications known to interfere with androgen metabolism cautiously avoided.
Contraindicated in patients with documented hypersensitivity to related chemical compounds.
Temporarily contraindicated if acute urinary retention occurs requiring emergent surgical intervention.
Use in females is contraindicated for any indication including off-label scenarios.

Drug Interactions

No major drug interactions have been extensively documented; however, caution is advised with other androgenic or antiandrogenic agents.
Concomitant use with alpha-1 blockers such as doxazosin may be prescribed and is generally safe and synergistic for BPH management.
Drugs metabolized by CYP3A4 enzymes may theoretically alter finasteride metabolism but clinical significance is minimal.
No significant interactions with common over-the-counter vitamins or herbal supplements are documented, yet patients should report all usage.
No effect on the pharmacokinetics of anticoagulants, antihypertensives, or diuretics noted.
No clinically relevant interactions reported with phosphodiesterase-5 inhibitors used for erectile dysfunction.
Co-administration with potent CYP3A4 inducers or inhibitors may necessitate monitoring for altered finasteride efficacy or side effects.
No significant interactions with lipid-lowering statins or antidiabetic agents reported.
Interactions with drugs affecting hormonal pathways, such as other 5-alpha-reductase inhibitors, are contraindicated.
Patients should inform their healthcare provider about all medications to monitor for unexpected adverse effects.
No reported significant interactions with fertility treatments, though finasteride itself may reduce fertility.
No evidence of interaction with nonsteroidal anti-inflammatory drugs (NSAIDs).
Finasteride does not interfere with the metabolism of cytochrome P450 substrates at clinically relevant levels.
No known interactions that alter the effectiveness of vaccines or anesthetic agents.
Monitoring is advised when initiating or discontinuing concomitant medications that may influence androgen levels.

Preparations Of The Drug

Proscar tablets contain 5 mg of finasteride in an oral solid dosage form.
Tablets are scored for ease of splitting to facilitate administration but dosing adjustments are not typically required.
Packaged in bottles with child-resistant caps to prevent accidental ingestion.
Stored at controlled room temperature away from moisture, heat, and light to preserve drug stability.
Dispensed with patient information leaflets highlighting contraindications, precautions, and handling instructions.
Available as brand-name Proscar and multiple generic equivalents containing identical active ingredient strength.
No injectable, topical, or liquid formulations for Proscar; all administration is oral.
Packaging sizes vary but typically supplied in 30 or 90 tablet bottles for monthly or quarterly therapy supplies.
Tablets are film-coated for patient compliance and ease of swallowing.
No known specialized compounded formulations in common clinical use for finasteride 5 mg.
Manufacturing conforms to FDA-approved standards for quality and purity of the finasteride active pharmaceutical ingredient.
Labeling includes warnings regarding handling by women and potential risks during pregnancy.
Prepared in compliance with standardized excipients ensuring consistent bioavailability.
Supplied with prescribing information delineating appropriate monitoring and use conditions.
Proscar is not combined in single dosage forms with other active ingredients; combination therapy requires separate agents.